Conaghan P G, Day R O
Department of Medicine, St Vincent's Hospital, Sydney, Australia.
Drug Saf. 1994 Oct;11(4):252-8. doi: 10.2165/00002018-199411040-00004.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are now commonly used for the treatment of acute gout, but caution is required in view of their adverse effects, especially in the elderly. Colchicine is still an effective acute agent, but care must be taken to monitor toxicity. Intra-articular glucocorticosteroid therapy is useful and very safe; oral steroids and corticotrophin (adrenocorticotrophic hormone) may have a small role in acute therapy and seem safe when used over short time spans. Low dose colchicine may have a cost and toxicity advantage over NSAIDs in the prophylaxis of gout when commencing therapy aimed at reducing elevated plasma urate concentrations. Allopurinol is more frequently used than uricosuric agents such as probenecid, and toxicity may be largely avoided by tailoring dosage schedules according to renal function.
非甾体抗炎药(NSAIDs)目前常用于治疗急性痛风,但鉴于其不良反应,尤其是在老年人中,使用时需谨慎。秋水仙碱仍然是一种有效的急性治疗药物,但必须注意监测其毒性。关节内注射糖皮质激素治疗有效且非常安全;口服类固醇和促肾上腺皮质激素在急性治疗中可能起较小作用,短期使用似乎是安全的。在开始旨在降低血浆尿酸浓度升高的治疗时,低剂量秋水仙碱在痛风预防方面可能比NSAIDs具有成本和毒性优势。与丙磺舒等促尿酸排泄药物相比,别嘌醇使用更为频繁,根据肾功能调整给药方案可在很大程度上避免毒性。